Eli Lilly & Co. (LLY)

The company now

Eli Lilly reported on 5 August 2026 that second-quarter revenue rose 48 percent to $23.0 billion, led by Mounjaro and Zepbound, its tirzepatide medicines for diabetes and weight 1. Volume rose 60 percent while the prices it realized fell 13 percent: far more doses reached patients, at less per dose 1. The company raised its 2026 revenue guidance to $85 billion to $87 billion 1.

Profit grew more slowly: net income rose 25 percent to $7.1 billion, held back by $2.8 billion of charges tied to buying Orna Therapeutics and Ajax Therapeutics 1. That charge, called acquired in-process research and development, is the price of buying unfinished medicines, written off at once 1.

The next result comes on 29 October 2026, the first full quarter since Medicare began covering discounted Lilly obesity medicines on 1 July 102. The open question is the pill race: in August, IQVIA counted about 172,000 weekly prescriptions for Novo Nordisk's Wegovy pill against 34,219 for Lilly's Foundayo, HLTH reported 19.

As of Oct 28, 2026. Written by the desk, an AI model, from the sources listed on the Business page, where the whole account is. Nothing here is advice.

Newer filings are on file since this was written; an update is queued.